BioPharmCatalyst
LightNews LightNews
biopharmcatalyst.bsky.social
BioPharmCatalyst
@biopharmcatalyst.bsky.social
350 followers 160 following 550 posts
FDA catalyst calendar, newsletters, and more. We do not provide investment advice or recommendations. #biotech #stocks

https://www.biopharmcatalyst.com/
Posts Replies Media Videos
biopharmcatalyst.bsky.social
$CAPR's Deramiocel met key endpoints in Phase 3 HOPE-3 for Duchenne MD, showing strong safety & efficacy; FDA resubmission planned.

www.biopharmcatalyst.com/news/2025/ca...
Daily Updates 12/03/25
export-download.canva.com
December 3, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
$PHVS surges after RAPIDe-3 trial success for deucrictibant in HAE; rapid symptom relief, strong stats, and good safety profile position it as a promising non-injectable acute treatment option.

www.biopharmcatalyst.com/news/2025/ph...
Pre-Market Updates 12/03/25
export-download.canva.com
December 3, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$JANX announced updated interim data from its Phase 1a and Phase 1b clinical trials of JANX007, a PSMA-directed TRACTr, in patients with metastatic castration-resistant prostate cancer (mCRPC).

See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/po...
December 2, 2025 at 9:50 PM
biopharmcatalyst.bsky.social
$PLRZ hits key scale-up for PL-14 nasal spray, paving way for 2026 trials and future commercialization.

www.biopharmcatalyst.com/news/2025/po...
Pre-Market Updates 12/02/25
export-download.canva.com
December 2, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$AKBA acquires QTTB’s C3d-FH fusion for rare kidney disease; Phase 2 trials for AKB-097, praliciguat start in 2026. $KALA $BCAX $BHC $BLTE $KTTA $XCUR $SHPH $ADTX $TOVX

www.biopharmcatalyst.com/news/2025/q3...
Daily Updates 12/01/25
export-download.canva.com
December 1, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
$BCAX reports 57% ORR, 83% DCR in Ph1b trial for recurring/metastatic head & neck cancer with ficerafusp alfa + pembrolizumab.

www.biopharmcatalyst.com/news/2025/bi...
Pre-Market Updates 12/01/25
export-download.canva.com
December 1, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$MBRX announces a 1-for-25 reverse stock split effective Dec 1, 2025, reducing outstanding shares.

www.biopharmcatalyst.com/news/2025/sc...
Daily Updates 11/28/25
export-download.canva.com
November 28, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
This week’s biotech watchlist highlights key ASH catalysts: ACLX, IMMX, ALLO & more. Stay updated with daily insights! More: biopharmcatalyst.com #biotech #stocks www.biopharmcatalyst.com/news/2025/bi...
November 28, 2025 at 9:15 PM
biopharmcatalyst.bsky.social
Pre-market movers: $KALA $SPRC $VRCA $PHGE $CMND $PMCB $MNDR $MESO $TYRA $GELS.

www.biopharmcatalyst.com/news/2025/ka...
Pre-Market Updates 11/28/25
export-download.canva.com
November 28, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$MBRX to execute a 1-for-25 reverse split on Dec 1, 2025, reducing outstanding shares.

www.biopharmcatalyst.com/news/2025/sc...
Daily Updates 11/27/25
export-download.canva.com
November 27, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
Pre-market movers: $KALA, $SPRC, $VRCA, $PHGE, $CMND, $PMCB, $MNDR, $MESO, $TYRA, $GELS

www.biopharmcatalyst.com/news/2025/ka...
Pre-Market Updates 11/27/25
export-download.canva.com
November 27, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$MBRX announces 1-for-25 reverse stock split effective Dec 1, 2025, reducing outstanding shares.

www.biopharmcatalyst.com/news/2025/sc...
Daily Updates 11/26/25
export-download.canva.com
November 26, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
$KALA secures $1.8M from David Lazar, aims for $6M total pending approval. Funding supports ongoing restructuring. $KALA $SPRC $VRCA $PHGE

www.biopharmcatalyst.com/news/2025/ka...
Pre-Market Updates 11/26/25
export-download.canva.com
November 26, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$ALUR: 12-month study shows 23% avg weight loss, 14% lean mass gain with Smart Capsule + tirzepatide; 100% adherence, no dropouts. #biotech

www.biopharmcatalyst.com/news/2025/qu...
Daily Updates 11/25/25
export-download.canva.com
November 25, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
$LNAI gets first LOI for AI-powered cancer cell therapy after promising preclinical results; plans Phase I trial for solid tumors following positive FDA feedback.

www.biopharmcatalyst.com/news/2025/lu...
Pre-Market Updates 11/25/25
export-download.canva.com
November 25, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
Piper Sandler reiterates Buy on $NXTC, $15 PT after $21.5M raise and pipeline updates. #BiotechNews

www.biopharmcatalyst.com/news/2025/pa...
Daily Updates 11/24/25
export-download.canva.com
November 24, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
$CLSD files for Chapter 11, plans asset sale including SCS Microinjector, licensing deals, and Phase 3/IND-ready programs. $ENLV $PMN $INSP $NVO $GNTA $ADTX $NAOV $SHPH $OABI

www.biopharmcatalyst.com/news/2025/cl...
Pre-Market Updates 11/24/25
export-download.canva.com
November 24, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$BCAB raises $7.5M via Pre-Paid Advance deals with YA II PN and Anson funds.

www.biopharmcatalyst.com/news/2025/bi...
Daily Updates 11/21/25
export-download.canva.com
November 21, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
BioPharmCatalyst Weekly Watchlist: Top small/mid-cap PDUFA catalysts this quarter—tickers include AGIO, OMER, CORT, MIST, NRXP. Get daily biotech insights and news. www.biopharmcatalyst.com/news/2025/bi...
November 21, 2025 at 9:15 PM
biopharmcatalyst.bsky.social
$KTTA: Phase 1 data for PAS-004 shows 71.4% disease control in BRAF-mutated tumors, no severe AEs, promising PK. Possible best-in-class MEK inhibitor. $CTNM $ANAB $SHPH $IKT $TELO $MNDR $VVOS $PBM $SINT

www.biopharmcatalyst.com/news/2025/pa...
Pre-Market Updates 11/21/25
export-download.canva.com
November 21, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$PBM secured GMP-grade iboga bark via PsyLabs, now processing 50kg for clinical ibogaine. Creating a sustainable, compliant supply chain for substance use disorder trials.

www.biopharmcatalyst.com/news/2025/ab...
Daily Updates 11/20/25
export-download.canva.com
November 20, 2025 at 9:30 PM
biopharmcatalyst.bsky.social
$ABT to buy $EXAS for $21B, adding top cancer diagnostics like Cologuard. Expands Abbott’s reach in early detection and precision oncology.

www.biopharmcatalyst.com/news/2025/in...
Pre-Market Updates 11/20/25
export-download.canva.com
November 20, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
$AGIO: Mitapivat met primary endpoint in Phase 3 sickle cell trial—improved hemoglobin, safe, but pain crisis reduction not statistically significant.

www.biopharmcatalyst.com/news/2025/ca...
Daily Updates 11/19/25
export-download.canva.com
November 19, 2025 at 9:31 PM
biopharmcatalyst.bsky.social
$CLLS reports >40% knock-in with CssDNA in HSPCs—3–5x higher than ssDNA—outperforming AAV6, advancing TALEN-based gene therapies.

www.biopharmcatalyst.com/news/2025/ce...
Pre-Market Updates 11/19/25
export-download.canva.com
November 19, 2025 at 1:40 PM
biopharmcatalyst.bsky.social
APYX prices 2.76M share offering at $3.62/share to raise funds.

www.biopharmcatalyst.com/news/2025/ca...
Daily Updates 11/18/25
export-download.canva.com
November 18, 2025 at 9:31 PM